Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome:
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity
Longer-term data from both adult patients showed sustained and new improvements across multiple efficacy measures and clinical domains following the completion of steroid taper (patient one: sat unassisted for first time in over a decade, normalized sleep, stabilized seizures; patient two: improved hand stereotypies and breathing, seizure-free for 8.5 months at 25% lower anti-seizure medication)
Initial data from first two pediatric patients showed improvements across multiple efficacy measures and clinical domains, with early evidence of developmental gains (patient one: improved hand function, grasp and gross motor coordination, gained visual reception and receptive language skills; patient two: gained ability to stand up from chair and walk up a stair, increase in seizure-free days)
IDMC approved Company’s request for early advancement to cohort two (high dose) in the REVEAL pediatric trial; dosing expected in Q3 2024 following IDMC review of initial safety data from the first high dose patient in the adolescent and adult trial
Company will host webcast today at 8:00 AM Eastern Time
https://ir.tayshagtx.com/news-relea...apies-announces-positive-clinical-data-across
- Forums
- ASX - By Stock
- NEU
- Competitors to Daybue
Competitors to Daybue, page-9
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.90 |
Change
-0.010(0.05%) |
Mkt cap ! $2.537B |
Open | High | Low | Value | Volume |
$19.88 | $20.07 | $19.73 | $2.523M | 126.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4 | $19.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.91 | 265 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 317 | 19.900 |
4 | 317 | 19.890 |
5 | 363 | 19.880 |
3 | 225 | 19.870 |
3 | 722 | 19.860 |
Price($) | Vol. | No. |
---|---|---|
19.930 | 605 | 10 |
19.940 | 363 | 12 |
19.950 | 261 | 3 |
19.960 | 1010 | 8 |
19.970 | 226 | 2 |
Last trade - 15.58pm 21/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online